BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Rahmani Moghadam E, Raei M, Kalantari M, Tavakol S, Mohammadinejad R, Najafi M, Tay FR, Makvandi P. Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy. ACS Comb Sci 2020;22:669-700. [PMID: 33095554 DOI: 10.1021/acscombsci.0c00099] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Piperno A, Sciortino MT, Giusto E, Montesi M, Panseri S, Scala A. Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles. Int J Nanomedicine 2021;16:5981-6002. [PMID: 34511901 DOI: 10.2147/IJN.S321329] [Reference Citation Analysis]
2 Wu Y, Zhang J, Ni J, Yang Z, Chen K, Zheng L, He Z. Polysaccharide-Based Lotus Seedpod Surface-Like Porous Microsphere as an Efficient Drug Carrier for Cancer Treatment. Cancer Manag Res 2021;13:4067-76. [PMID: 34040445 DOI: 10.2147/CMAR.S291473] [Reference Citation Analysis]
3 Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MM, Aljabali AAA, Awidi A. siRNA: Mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol 2021;905:174178. [PMID: 34044011 DOI: 10.1016/j.ejphar.2021.174178] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Subhan A, Attia SA, P Torchilin V. Targeted siRNA nanotherapeutics against breast and ovarian metastatic cancer: a comprehensive review of the literature. Nanomedicine (Lond) 2022;17:41-64. [PMID: 34930021 DOI: 10.2217/nnm-2021-0207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Işıklan N, Hussien NA, Türk M. Synthesis and drug delivery performance of gelatin-decorated magnetic graphene oxide nanoplatform. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2021;616:126256. [DOI: 10.1016/j.colsurfa.2021.126256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zare EN, Zheng X, Makvandi P, Gheybi H, Sartorius R, Yiu CKY, Adeli M, Wu A, Zarrabi A, Varma RS, Tay FR. Nonspherical Metal‐Based Nanoarchitectures: Synthesis and Impact of Size, Shape, and Composition on Their Biological Activity. Small 2021;17:2007073. [DOI: 10.1002/smll.202007073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, García-Couce J, Tavakol S, Moghassemi S, Dadashzadeh A, Makvandi P, Pardakhty A, Aghaei Afshar A, Seyfoddin A. Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems. ACS Biomater Sci Eng 2022;8:1763-90. [PMID: 35439408 DOI: 10.1021/acsbiomaterials.2c00026] [Reference Citation Analysis]
8 Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. J Hepatocell Carcinoma 2021;8:1415-44. [PMID: 34858888 DOI: 10.2147/JHC.S336858] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, Zarrabi A, Goldman A, Ashrafizadeh M, Orive G. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 2021:S1359-6446(21)00428-1. [PMID: 34624510 DOI: 10.1016/j.drudis.2021.09.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 18.0] [Reference Citation Analysis]
10 Anwar DM, El-Sayed M, Reda A, Fang JY, Khattab SN, Elzoghby AO. Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes. Expert Opin Drug Deliv 2021;:1-17. [PMID: 34254868 DOI: 10.1080/17425247.2021.1955853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Gao H, Xian G, Zhong G, Huang B, Liang S, Zeng Q, Liu Y. Alleviation of doxorubicin-induced cardiomyocyte death through miR-147-y-mediated mitophagy. Biochem Biophys Res Commun 2022;609:176-82. [PMID: 35452958 DOI: 10.1016/j.bbrc.2022.04.013] [Reference Citation Analysis]
12 Makvandi P, Josic U, Delfi M, Pinelli F, Jahed V, Kaya E, Ashrafizadeh M, Zarepour A, Rossi F, Zarrabi A, Agarwal T, Zare EN, Ghomi M, Kumar Maiti T, Breschi L, Tay FR. Drug Delivery (Nano)Platforms for Oral and Dental Applications: Tissue Regeneration, Infection Control, and Cancer Management. Adv Sci (Weinh) 2021;8:2004014. [PMID: 33898183 DOI: 10.1002/advs.202004014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 34.0] [Reference Citation Analysis]
13 Mousazadeh H, Bonabi E, Zarghami N. Stimulus-responsive drug/gene delivery system based on polyethylenimine cyclodextrin nanoparticles for potential cancer therapy. Carbohydr Polym 2022;276:118747. [PMID: 34823779 DOI: 10.1016/j.carbpol.2021.118747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
14 Mirzaei S, Gholami MH, Ang HL, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Delfi M, Khan H, Ashrafizadeh M, Sethi G, Kumar AP. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 2021;10:3348. [PMID: 34943856 DOI: 10.3390/cells10123348] [Reference Citation Analysis]
15 Mahabady MK, Mirzaei S, Saebfar H, Gholami MH, Zabolian A, Hushmandi K, Hashemi F, Tajik F, Hashemi M, Kumar AP, Aref AR, Zarrabi A, Khan H, Hamblin MR, Nuri Ertas Y, Samarghandian S. Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity. J Cell Physiol 2022;237:2309-44. [PMID: 35437787 DOI: 10.1002/jcp.30751] [Reference Citation Analysis]
16 Paskeh MDA, Mehrabi A, Gholami MH, Zabolian A, Ranjbar E, Saleki H, Ranjbar A, Hashemi M, Ertas YN, Hushmandi K, Mirzaei S, Ashrafizadeh M, Zarrabi A, Samarghandian S. EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects. Biomed Pharmacother 2021;146:112532. [PMID: 34906772 DOI: 10.1016/j.biopha.2021.112532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ashrafizadeh M, Zarrabi A, Karimi‐maleh H, Taheriazam A, Mirzaei S, Hashemi M, Hushmandi K, Makvandi P, Nazarzadeh Zare E, Sharifi E, Goel A, Wang L, Ren J, Nuri Ertas Y, Kumar AP, Wang Y, Rabiee N, Sethi G, Ma Z. (Nano)platforms in bladder cancer therapy: Challenges and opportunities. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10353] [Reference Citation Analysis]
18 Makvandi P, Zarepour A, Zheng X, Agarwal T, Ghomi M, Sartorius R, Zare EN, Zarrabi A, Wu A, Maiti TK, Smith BR, Varma RS, Tay FR, Mattoli V. Non-spherical nanostructures in nanomedicine: From noble metal nanorods to transition metal dichalcogenide nanosheets. Applied Materials Today 2021;24:101107. [DOI: 10.1016/j.apmt.2021.101107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
19 Mubeen B, Rasool MG, Ullah I, Rasool R, Imam SS, Alshehri S, Ghoneim MM, Alzarea SI, Nadeem MS, Kazmi I. Phytochemicals Mediated Synthesis of AuNPs from Citrullus colocynthis and Their Characterization. Molecules 2022;27:1300. [PMID: 35209086 DOI: 10.3390/molecules27041300] [Reference Citation Analysis]
20 Lin W, Li C, Xu N, Watanabe M, Xue R, Xu A, Araki M, Sun R, Liu C, Nasu Y, Huang P. Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment. Int J Nanomedicine 2021;16:2775-87. [PMID: 33880023 DOI: 10.2147/IJN.S301552] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Madamsetty VS, Tavakol S, Moghassemi S, Dadashzadeh A, Schneible JD, Fatemi I, Shirvani A, Zarrabi A, Azedi F, Dehshahri A, Aghaei Afshar A, Aghaabbasi K, Pardakhty A, Mohammadinejad R, Kesharwani P. Chitosan: A versatile bio-platform for breast cancer theranostics. J Control Release 2021;341:733-52. [PMID: 34906606 DOI: 10.1016/j.jconrel.2021.12.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
22 Hashemzadeh N, Dolatkhah M, Aghanejad A, Barzegar-Jalali M, Omidi Y, Adibkia K, Barar J. Folate receptor-mediated delivery of 1-MDT-loaded mesoporous silica magnetic nanoparticles to target breast cancer cells. Nanomedicine (Lond) 2021;16:2137-54. [PMID: 34530630 DOI: 10.2217/nnm-2021-0176] [Reference Citation Analysis]
23 Liu J, Ren S, Zhang X, Feng Y, Qiu Z, Ma L, Huang J. Preparation, Biocompatibility and Antitumor Activity of Nanodelivery System Targeting Breast Cancer Base on a Silica Nanoparticle. Onco Targets Ther 2021;14:3429-42. [PMID: 34079288 DOI: 10.2147/OTT.S291142] [Reference Citation Analysis]
24 Ashrafizadeh M, Aghamiri S, Tan SC, Zarrabi A, Sharifi E, Rabiee N, Kadumudi FB, Pirouz AD, Delfi M, Byrappa K, Thakur VK, Sharath Kumar KS, Girish YR, Zandsalimi F, Zare EN, Orive G, Tay F, Hushmandi K, Kumar AP, Karaman C, Karimi-maleh H, Mostafavi E, Makvandi P, Wang Y. Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology. Nano Today 2022;45:101532. [DOI: 10.1016/j.nantod.2022.101532] [Reference Citation Analysis]
25 Park SC, Heo H, Jang MK. Polyethylenimine grafted-chitosan based Gambogic acid copolymers for targeting cancer cells overexpressing transferrin receptors. Carbohydr Polym 2022;277:118755. [PMID: 34893210 DOI: 10.1016/j.carbpol.2021.118755] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Abadi AJ, Mirzaei S, Mahabady MK, Hashemi F, Zabolian A, Hashemi F, Raee P, Aghamiri S, Ashrafizadeh M, Aref AR, Hamblin MR, Hushmandi K, Zarrabi A, Sethi G. Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects. Phytother Res 2021. [PMID: 34697839 DOI: 10.1002/ptr.7305] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhao Y, Liu T, Ardana A, Fletcher NL, Houston ZH, Blakey I, Thurecht KJ. Investigation of a Dual siRNA/Chemotherapy Delivery System for Breast Cancer Therapy. ACS Omega 2022;7:17119-27. [PMID: 35647423 DOI: 10.1021/acsomega.2c00620] [Reference Citation Analysis]
28 Moammeri A, Abbaspour K, Zafarian A, Jamshidifar E, Motasadizadeh H, Dabbagh Moghaddam F, Salehi Z, Makvandi P, Dinarvand R. pH-Responsive, Adorned Nanoniosomes for Codelivery of Cisplatin and Epirubicin: Synergistic Treatment of Tumorigenesis Breast Cancer. ACS Appl Bio Mater 2022. [PMID: 35129960 DOI: 10.1021/acsabm.1c01107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
29 Tang Y, Jia C, Wang Y, Wan W, Li H, Huang G, Zhang X. Lactate Consumption via Cascaded Enzymes Combined VEGF siRNA for Synergistic Anti-Proliferation and Anti-Angiogenesis Therapy of Tumors. Adv Healthc Mater 2021;10:e2100799. [PMID: 34310079 DOI: 10.1002/adhm.202100799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Abd El-Hameed NM, Abd El-Aleem SA, Khattab MA, Ali AH, Mohammed HH. Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): Prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH). Life Sci 2021;285:119983. [PMID: 34599938 DOI: 10.1016/j.lfs.2021.119983] [Reference Citation Analysis]
31 Sadrkhanloo M, Entezari M, Orouei S, Ghollasi M, Fathi N, Rezaei S, Hejazi ES, Kakavand A, Saebfar H, Hashemi M, Goharrizi MASB, Salimimoghadam S, Rashidi M, Taheriazam A, Samarghandian S. STAT3-EMT axis in tumors: modulation of cancer metastasis, stemness and therapy response. Pharmacol Res 2022;:106311. [PMID: 35716914 DOI: 10.1016/j.phrs.2022.106311] [Reference Citation Analysis]